Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Wave Life Sciences (WVE) Enterprise Value (2016 - 2026)

Wave Life Sciences (WVE) has disclosed Enterprise Value for 12 consecutive years, with -$544.6 million as the latest value for Q1 2026.

  • For Q1 2026, Enterprise Value fell 124.05% year-over-year to -$544.6 million; the TTM value through Mar 2026 reached -$544.6 million, down 124.05%, while the annual FY2025 figure was -$602.1 million, 99.31% down from the prior year.
  • Enterprise Value hit -$544.6 million in Q1 2026 for Wave Life Sciences, up from -$602.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$88.5 million in Q4 2022 and bottomed at -$602.1 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$235.8 million, with a median of -$196.2 million recorded in 2025.
  • Year-over-year, Enterprise Value surged 41.22% in 2022 and then tumbled 126.39% in 2023.
  • Wave Life Sciences' Enterprise Value stood at -$88.5 million in 2022, then plummeted by 126.39% to -$200.4 million in 2023, then crashed by 50.77% to -$302.1 million in 2024, then tumbled by 99.31% to -$602.1 million in 2025, then increased by 9.55% to -$544.6 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$544.6 million, -$602.1 million, and -$196.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.